Last updated: March 12, 2026
What is NDC 69452-0332?
NDC 69452-0332 corresponds to Droxidopa (NDC 69452-0332-01), a prescription medication approved by the FDA for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). It is marketed under the brand name Northera.
Market Overview
Indications and Therapy Landscape
Droxidopa treats nOH, a condition often associated with Parkinson’s disease, multiple system atrophy, and pure autonomic failure. The prevalence of nOH in the U.S. is estimated at 20-30 cases per 100,000 individuals, with Parkinson's disease-related nOH being the most common.
Competitive Environment
Key competitors include:
- Midodrine (Proamatine): An alpha-1 adrenergic agonist, FDA-approved for similar indications.
- Fludrocortisone: An off-label treatment used for nOH.
- Other emerging therapies: Several pipeline drugs target neurogenic orthostatic hypotension, but none hold current approval status comparable to droxidopa.
Market Drivers
- Increasing diagnosis rates of Parkinson’s and other neurodegenerative diseases.
- Greater awareness of nOH.
- Expanded insurance coverage following FDA approval.
- COVID-19 pandemic influence: possible increased focus on autonomic disorders due to neurodegeneration.
Sales and Revenue Data
- 2022 Sales: Estimated at approximately $180 million in the U.S., according to IQVIA data.
- Prescription Trends: Monthly prescriptions have increased by roughly 10-15% year-over-year since 2020, indicating growing adoption.
- Market Penetration: Currently estimated at 35-40% of eligible patients.
Pricing Analysis
Current Pricing Overview
- Average Wholesale Price (AWP): Approx. $3.10 per capsule.
- Average Selling Price (ASP): Approx. $2.75 per capsule.
- Common Prescription Size: 100 capsules per month for typical treatment.
Reimbursement and Cost Dynamics
- Insurance Coverage: Generally favorable along Medicaid, Medicare Part D, and private insurance plans.
- Patient Cost: Estimated copays range from $10 to $50 per month depending on insurance tier.
- Manufacturer Pricing Strategy: Maintains a relatively stable AWP to sustain revenue, with discounts provided via rebates.
Price Projections (Next 5 Years)
| Year |
Estimated AWP per Capsule |
Projected U.S. Sales |
Market Penetration |
Notes |
| 2023 |
$3.10 |
$180 million |
35% |
Baseline, current market size |
| 2024 |
$3.15 |
$210 million |
40% |
Slight price increase, expanded indications |
| 2025 |
$3.20 |
$250 million |
45% |
Increased awareness, competitive pressure stabilizes |
| 2026 |
$3.25 |
$290 million |
50% |
Entry into new markets, price stabilization |
| 2027 |
$3.30 |
$330 million |
55% |
Market growth continues, pipeline development impact |
Assumptions
- Market growth driven by increased diagnosis and use.
- No major price cuts due to new entrants or biosimilar competition.
- Reimbursement policies remain favorable.
Risks to Price Projections
- Introduction of biosimilar or generic versions.
- Significant policy changes affecting drug reimbursement.
- Emergence of alternative therapies with better efficacy or safety profile.
Regulatory and Policy Impact
- The FDA approval process for expanding indications may enhance market size.
- Payer shifts towards value-based agreements could pressure pricing.
- CMS reforms targeting drug pricing could influence net revenue.
Key Takeaways
- NDC 69452-0332 (Droxidopa) is a niche, growing therapy for nOH with a stable market primarily driven by Parkinson’s-related neurodegeneration.
- Sales are expected to grow steadily through 2027, with modest price increases aligned with inflation and market expansion.
- Price sensitivity remains moderate; potential threats include biosimilars and policy shifts.
- Current reimbursement strategies support sustainable margins, but future changes could constrain pricing.
Frequently Asked Questions
1. Will droxidopa’s price increase significantly in the next five years?
Likely small, incremental increases to reflect inflation, with overall stable pricing given current market dynamics.
2. What are the main factors influencing droxidopa’s market growth?
Rising neurodegenerative disease prevalence, increased diagnosis of nOH, and expanded insurance coverage.
3. How does droxidopa compare with its competitors in pricing?
It maintains a slightly higher price point than off-label treatments like fludrocortisone but is generally aligned with other FDA-approved therapies such as midodrine.
4. Could biosimilars or generics emerge, impacting the price?
Possible once patent exclusivity or market exclusivity expires; currently, no biosimilar options are available.
5. How will policy changes affect droxidopa’s market and pricing?
Reimbursement reforms and drug pricing caps could exert downward pressure on prices; however, the niche indication may limit major impacts.
References
- IQVIA. (2023). Pharmaceutical Sales Data. [Data set].
- U.S. Food and Drug Administration. (2019). Northera (droxidopa) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/205560s000lbl.pdf
- Centers for Disease Control and Prevention. (2021). Parkinson’s Disease Statistics. https://www.cdc.gov/healthcommunication/toolstemplates/entertainmented/tips/parkinsons.html
- GlobalData. (2023). Neurodegenerative Disorder Market Analysis. [Market report].
- CMS. (2022). Medicare Drug Reimbursement Policies. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-reimbursement
